Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07662018 · ClinicalTrials.gov registry record
Prospective Observational Study of Outcomes After Gemcitabine, Docetaxel, Melphalan, and Carboplatin With Autologous Stem Cell Transplantation in Pediatric Relapsed/Refractory Germ Cell Tumors
A clinical trial, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- 30
- Enrollment target
NCT07662018: Recruiting study, sponsored by M.D. Anderson Cancer Center.
NCT07662018 is a clinical trial that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07662018 is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- 30 participants
- Enrollment target
Study Summary
To collect information about treatment outcomes in pediatric and adolescent patients with relapsed/refractory germ cells tumors who receive GemDMC with an ASCT.
Interventions
- DRUG Melphalan
- DRUG Carboplatin
- DRUG Docetaxel
- DRUG Gemcitabine (GEM)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-06-05 |
| Est. Completion | 2033-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07662018
The ClinicalTrials.gov registry entry for NCT07662018 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Melphalan is the first listed.
NCT07662018 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07662018 about?
NCT07662018 is a clinical study titled "Prospective Observational Study of Outcomes After Gemcitabine, Docetaxel, Melphalan, and Carboplatin With Autologous Stem Cell Transplantation in Pediatric Relapsed/Refractory Germ Cell Tumors". To collect information about treatment outcomes in pediatric and adolescent patients with relapsed/refractory germ cells tumors who receive GemDMC with an ASCT.
What is the current status of trial NCT07662018?
This trial is currently recruiting. The enrollment target is 30 participants. The study started on 2026-06-05. Estimated completion is 2033-12-31.
What interventions are being tested in trial NCT07662018?
The interventions under investigation include: Melphalan (DRUG), Carboplatin (DRUG), Docetaxel (DRUG), Gemcitabine (GEM) (DRUG).
Who is sponsoring clinical trial NCT07662018?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.